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Abstract
Background In the context of priority setting, a differential cost-effectiveness threshold can be used to reflect a higher societal 
willingness to pay for quality-adjusted life-year gains in the worse off. However, uncertainty in the estimate of severity can 
lead to problems when evaluating the outcomes of cost-effectiveness analyses.
Objectives This study standardizes the assessment of severity, integrates its uncertainty with the uncertainty in cost-effec-
tiveness results and provides decision makers with a new estimate: the severity-adjusted probability of being cost effective.
Methods Severity is expressed in proportional and absolute shortfall and estimated using life tables and country-specific EQ-5D 
values. We use the three severity-based cost-effectiveness thresholds (€20.000, €50.000 and €80.000, per QALY) adopted in The 
Netherlands. We exemplify procedures of integrating uncertainty with a stylized example of a hypothetical oncology treatment.
Results Applying our methods, taking into account the uncertainty in the cost-effectiveness results and in the estimation 
of severity identifies the likelihood of an intervention being cost effective when there is uncertainty about the appropriate 
severity-based cost-effectiveness threshold.
Conclusions Higher willingness-to-pay thresholds for severe diseases are implemented in countries to reflect societal con-
cerns for an equitable distribution of resources. However, the estimates of severity are uncertain, patient populations are 
heterogeneous, and this can be accounted for with the severity-adjusted probability of being cost effective proposed in this 
study. The application to the Netherlands suggests that not adopting the new method could result in incorrect decisions in 
the reimbursement of new health technologies.
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Key Points for Decision Makers 
Some societies have policies that indicate higher willing-
ness to pay for the worse-off.
The Netherlands has formally introduced differential 
thresholds based on severity of illness of €20.000, 
€50.000 and €80.000 per QALY based on estimates of 
proportional shortfall.
The uncertainty in the estimation of severity and cost 
effectiveness should be integrated to estimate the 
severity-adjusted probability of being cost effective.
1 Introduction
In the context of priority setting in health care, an impor-
tant issue is whether or not to give more weight to health 
gains in particular circumstances or beneficiaries. Impor-
tant examples include gains at the end of life, in the young 
or in severely ill patients. If distributional concerns exist 
and are to be included in (decisions based on) economic 
evaluations, one way of doing so is by using differential 
cost-effectiveness thresholds based on equity classes. In 
the Netherlands, for instance, severity-based equity classes 
define three thresholds: a threshold of €80,000 per QALY 
applies to the most severe conditions with poor prognoses 
such as aggressive cancers, and two lower thresholds are 
used for conditions with a relatively better outlook. For 
example, a new heart failure treatment had to be evalu-
ated against a €50,000 per QALY threshold according to 
the guidelines [1]. The estimate of severity, however, is 
uncertain and this can cause issues in the evaluation and 
interpretation of cost-effectiveness results. For example, in 
April 2019 the appraisal committee of the Dutch National 
Health Care Institute had difficulties evaluating the cost 
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effectiveness of venetoclax as a treatment for chronic lym-
phocytic leukaemia. The committee noted that the appli-
cable threshold for this condition could be either €80,000 
or €50,000 per QALY due to uncertainty in the estimate 
of severity. Since the treatment would only be cost effec-
tive with the higher threshold, the committee noted that 
the uncertainty of the threshold caused great uncertainty 
about the cost effectiveness of the treatment [2].
Severity of illness generally reflects the (average) 
amount of health lost in a population affected by some ill-
ness. Using differential cost-effectiveness thresholds based 
on severity rather than a fixed threshold is assumed to 
result in a more equitable distribution of resources, despite 
a potential sacrifice in total aggregate health in society. 
Indeed, it seems that “people are, on the whole, willing to 
sacrifice aggregate health in order to give priority to the 
severely ill” [3]. However, operationalizing severity into 
measurable units is not straightforward [4] and decision 
makers and scholars alike are in disagreement on the opti-
mal approach. The disagreement entails both the principles 
underlying severity weighting (i.e. how to define who is 
worse off) and the operationalization of the principle (i.e. 
how to come from the principle to quantitative expressions 
of severity) [5].
Several governments and relevant authorities have 
instruments in place to set priorities based on principles 
other than health maximization. In the UK, incremental 
cost-effectiveness ratios above the upper threshold range 
of £30,000 may be acceptable for life-extending end-of-
life treatments meeting certain criteria, such as extending 
life by at least 3 months [6]. The need to take severity into 
account is also reflected in health policies in countries 
such as Finland, France, Germany, Spain and Sweden [2], 
although not necessarily in a quantified manner or directly 
related to differential cost-effectiveness thresholds.
The Netherlands and Norway both explicitly integrate 
severity in their decision-making process but have pro-
posed differential thresholds based on two distinct prin-
ciples and operationalization of severity. In the Nether-
lands, a decision-making framework has been adopted 
with three primary criteria: necessity, effectiveness and 
efficiency (cost effectiveness). Equity considerations are 
integrated in this framework within the necessity criterion 
(the [medical] need to insure the intervention) and in the 
efficiency criterion through differential cost-effectiveness 
thresholds for increasing severity [5]. There are three 
increasing cost-effectiveness thresholds, which are asso-
ciated with three increasing categories of ‘severity’ of the 
condition that the intervention under evaluation targets 
[7]. The severity categories are based on the proportion 
of quality-adjusted life-years (QALYs) lost relative to 
quality-adjusted life expectancy (QALE) of matched (on 
age and gender) non-ill individuals, a principle referred 
to as proportional shortfall [8]. Recently, a review of the 
application of proportional shortfall in the Netherlands 
was published [9]. Aside from the Netherlands, Norway 
also envisions a future with a differential threshold based 
on severity [10], and has proposed a categorical and con-
tinuous severity criterion based on absolute QALYs lost 
relative to QALE of matched (on age and gender) non-ill 
individuals, a principle referred to as absolute shortfall.
An often overlooked issue, which to our knowledge has 
not previously been addressed in the literature on severity-
based differential thresholds, is the uncertainty and het-
erogeneity in the estimate of severity. Quantifications of 
severity that include estimations of future QALYs, regard-
less of the specific unit of measurement for severity, are 
uncertain due to several reasons, among which is uncer-
tainty in future health of patients.
This paper first suggests standardizing the method to 
estimate two measures of severity: absolute and propor-
tional shortfall. Second, a method is presented on how to 
combine the uncertainty of severity with the uncertainty 
in a cost-effectiveness model. This is done to address the 
fundamental problem decision makers face: since nei-
ther the exact incremental cost-effectiveness ratio nor the 
exact threshold can be known, we may need to estimate 
the severity-adjusted probability of being cost effective as 
an alternative to, or alongside, cost-effectiveness accept-
ability curves (CEACs) [11]. Finally, this paper proposes 
a method for doing so and highlights its use in the Neth-
erlands in a stylized example.
2  Background
A healthcare intervention can be seen as welfare improving 
if its additional benefits outweigh its additional costs. Cost-
utility analysis (CUA), “the primary method for evaluating 
policy under a utilitarian ethic” [12], expresses benefits in 
terms of QALYs and an associated monetary value of these 
QALYs, giving the following decision criterion for incre-
mental net monetary benefit for adopting a new healthcare 
intervention:
where v is the consumption value of health, or the societal 
willingness to pay (WTP) for a QALY (distinctively dif-
ferent from the ‘k-threshold’, which reflects the marginal 
returns on health spending or health opportunity costs from 
a healthcare perspective1), ΔQ is the difference in QALYs 
(1)vΔQ − ΔC > 0,
1 Note that in using a healthcare perspective with different health 
opportunity cost thresholds to reflect equity concerns, similar issues 
arise as discussed here. Here, we assume, for simplicity’s sake, opti-
mal and flexible budgets.
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between the current standard of care and the new medi-
cal intervention and ΔC is the difference in societal costs 
between the current standard of care and the new medical 
intervention. The decision framework of Eq. 1 gives equal 
weight to all QALYs gained, irrespective of gaining them in 
those with poor or good health (or any other relevant distinc-
tion between groups). The formula can be adjusted to take 
into account differential thresholds based on equity consid-
erations such as severity [5]:
The subscript i represents the possibility to consider the 
context of QALY gains and to attach different values to 
QALY gains occurring in different ‘equity classes’. Hence, 
when QALYs are gained in that specific equity class, a dif-
ferent monetary value of a QALY may apply to account for 
different societal WTP for the worse off, aiming to achieve 
a better balance between equity and efficiency [13]. Note 
that this is equal to attaching equity weights to the QALY 
gains when these equity weights reflect the relative societal 
value of these gains [14]. While many different elements 
may define an equity class [15], this paper limits the exam-
ples to equity classes based on severity. Also, it is worth 
mentioning that empirical estimates of both k-thresholds 
and v-thresholds are surrounded with uncertainty. For exam-
ple, the Dutch estimate for k of €41,000 has a 95% credible 
interval of 25,900–110,400 [16], which could be taken into 
account when representing decision uncertainty. However, it 
typically is not the case that thresholds defined in a country 
are a one-on-one representation of empirical estimates and 
hence may also represent some fixed value or value range 
set by an appropriate authority.
A simplification in the often used notation in Eq. 2 is 
that it does not take into account the heterogeneity of equity 
classes within the population in which QALYs are gained. 
Simply put, Eq. 2 assumes homogeneity in patients in terms 
of equity class or implicitly uses an average, while not all 
patients in which QALYs are gained are equally worse off. 
In treating specific infections, for instance, some patients 
may be severely ill while others receiving the treatment are 
only mildly ill. To account for this variation, Eq. 2 can be 
rewritten to:
to allow every patient j to belong to any of the i equity 
classes. However, only in patient-level simulation models 
will it be feasible to identify the individual equity class since 
only in those models a patient-specific value for Q and C 
is available. Therefore, we present an approach here that 
takes heterogeneity as well as uncertainty of equity classes 
into account using input from the probabilistic sensitivity 
(2)viΔQi − ΔC > 0,
(3)
N∑
j=1
n∑
i=1
(vijΔQij − ΔCij) > 0,
analysis, and is hence easier to implement in Markov-type 
models. To do so, we first need to define severity and then 
describe how to consistently estimate it. Note that it is irrel-
evant for the calculation whether equity classes are defined 
as continuous classes (many values for each i) or categori-
cally defined classes.
2.1  Severity‑Based Equity Classes 
in the Netherlands
In the Netherlands, efforts have been made to formally 
include severity-based equity classes in guidelines for eco-
nomic evaluations in terms of proportional shortfall (PS), 
which describes absolute shortfall (AS) as a proportion of 
QALE. We first describe AS, then PS.
The absolute loss in QALE is referred to as AS:
Here we define Qn as the country-specific general popu-
lation average QALE, adjusted for age and gender of the 
patients (i.e. the health that could have occurred had the 
patient not been ill) and Qd is the average patient-popula-
tion-specific QALE (i.e. QALE in the indication area of the 
medical intervention).
In the Netherlands, three equity classes have been 
defined based on the (average) proportion of normal life 
expectancy at a given age that is lost in a population due 
to the relevant disease, referred to as PS [8]. The ‘popu-
lation’ refers to the target population of a given inter-
vention as described in, for example, a reimbursement 
dossier. In a letter to the Minister of Health, the Dutch 
National Health Care Institute proposed that for a PS 
between 10 and 40% of remaining QALE, a WTP thresh-
old of €20,000 applies [7]. Similarly, between 41 and 
70%, and > 71%, the threshold is, respectively, €50,000 
and €80,000 per QALY. PS is calculated as described 
in Eq. 4 and expresses the number of QALYs lost in a 
population as a proportion of the number of QALYs that 
would be incurred in the general population matched for 
age and gender:
The relationship between AS and PS is.
Equations 4 and 5 describe the calculation of AS and 
PS. For several years, there was no clear guidance on how 
to calculate the constituting elements Qn and Qd , but in 
2018 both Dutch and Norwegian reimbursement agencies 
have documented its calculation [17, 18], and hence for 
AS and PS there are policy documents available. How-
ever, both guidelines do not deal with uncertainty in the 
(4)AS = Qn − Qd.
(5)PS =
AS
Qn
.
(6)AS = PS × Qn
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estimates, and are not aligned in the methods to be used 
to calculate Qn , both of which we address here.
First, we describe a consistent and reproducible way of 
calculating Qn and suggest use of undiscounted QALYs 
in the comparator of the health economic model for the 
estimation of Qd . Note that with equating Qd to the undis-
counted comparator in economic evaluations, we effec-
tively state that population-specific QALE in the indi-
cation area of the condition should be calculated taking 
into account the current standard of care. This is different 
from earlier formulations that calculated Qd by subtract-
ing “a patient’s remaining QALY expectancy without 
treatment” from Qn [8]. Hence, while we look at QALY 
losses occurring given current standards of care, previ-
ous definitions used the situation without any treatment 
as comparator. This choice will be elaborated on further 
below. Then, we describe how we integrate uncertainty 
from the health economic model with uncertainty in the 
estimate of Qn.
3  Definitions for Quality‑Adjusted Life 
Expectancy (QALE)
Here, we first describe a standardized estimation of Qn 
and Qd for use in AS and PS calculations and then proceed 
to suggest how the severity-adjusted cost-effectiveness 
threshold can be calculated for differential thresholds.
3.1  Normal QALE: Qn
Normal-period QALE reflects what the average population 
can expect to incur in terms of numbers of QALYs remain-
ing at any given age and gender. Hence, QALE requires an 
estimation of life expectancy and quality of life by age and 
gender. We propose to consistently estimate life expectancy 
using life tables and source of utility values for QALY com-
putation that is consistent with the estimates for utility used 
in economic evaluation.
Here we use data and the methods protocol of the Human 
Mortality Database with 2013 country- and gender-specific 
mortality rates and a half-cycle correction [19]. The life 
tables are closed at 99 + years using a constant mortality risk 
from that age onwards. Quality of life is integrated in the life 
tables using EQ-5D-3L-based utility values stratified for 14 
age groups (from 20 to 85 years) and gender in the life tables 
[20]. Quality adjustment is based on EQ-5D since, in the 
Netherlands, this tool is requested as the reference case for 
the computation of QALYs in economic evaluations. Thus, 
it is consistent to also use EQ-5D for the computation of 
Qn , especially if Qd is taken from the undiscounted number 
of EQ-5D-based QALYs for the comparator in the health 
economic model. In estimation of QALE for this study, 
assumptions had to be made about quality of life for age 
groups < 20 years and > 85 years due to missing data. Qual-
ity of life for ages 0–20 years is assumed at 0.958, which 
is 0.02 higher than the Dutch EQ-5D-3L population norm 
for > 20- to 24-year olds and corresponds to the Dutch EQ-
5D-5L estimate for the population aged 18–20 years [21]. 
For age > 85 years, the utility value is assumed to be the 
same as in the age group 80–85 years. We are aware that 
equivalence between EQ-5D-3L and 5L utility values is not 
established [22], but population norms for EQ-5D-5L are 
not (yet) available for the Netherlands.
Note that there are two elements of uncertainty in the esti-
mation of Qn : the applicability of the 2013 mortality rates to 
the population at the time of estimation and the heterogene-
ity in quality-of-life estimates. Since uncertainty regarding 
mortality rates is negligible, only heterogeneity regarding 
quality of life is included, detailed later on.
3.2  Patient‑Population‑Specific QALE: Qd
Patient-population-specific QALE should be calculated for 
the population for which a cost-effectiveness model is sub-
mitted since this model reflects the population eligible for 
treatment. Hence, Qd is equal to the modelled total number 
of undiscounted QALYs with standard of care at the mean 
age of the model population with country-specific quality-
of-life values, which best represent patient QALE, using a 
lifetime horizon. Therefore, ‘standard of care’ is chosen as 
reference point rather than ‘no treatment’. Given that this is 
a deviation from traditional calculations, we highlight a few 
reasons why this was chosen. First, this estimate realistically 
reflects current survival and quality of life of those with the 
condition and hence provides the relevant background situ-
ation for the current decision to fund a new intervention. 
The better current treatment is, the lower the necessity to 
improve it even further. This is intuitive. Second, this pro-
posed estimate aligns with the perspective of the decision 
maker who has to decide if the marginal benefit of the new 
treatment weighs up to its marginal costs, relative to the cur-
rent treatment. Third, in the Netherlands, severity is calcu-
lated in the context of necessity of treatment, which refers to 
the claim on solidarity new treatments can make. It appears 
that, even though previous documents have referred to Qd 
as QALE ‘with the condition’ in a more general sense [23], 
this interpretation of Qd as ‘with the condition and current 
standard of care’ relates more closely to additional claims 
on solidarity. Fourth, given that equity weights often aim 
to (somehow) reflect societal preferences for distribution, it 
seems that a realistic alternative (like the comparator) would 
better align with preferences for treating particular diseases 
than hypothetical ones. Finally, finding estimates of quality 
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of life in case of not treating a disease may be difficult for 
all diseases for which good treatments exist.
As a consequence, the value of Qd and the severity of 
disease in the relevant population is dynamic and follows 
developments in current standard of care. When direct 
access to the economic model is available, the estimates of 
the probabilistic sensitivity analysis can be used to reflect the 
distribution (capturing both heterogeneity and uncertainty) 
of potential estimates for Qd.2
To provide an example illustrating the above and the 
impact of uncertainty, consider a new therapy (T) that was 
developed for a condition in a population of males with a 
mean age of 33 years, for which current standard of care 
results in an average QALE 
(
Qd
)
 of 12.25 years. Life tables 
combined with Dutch quality-of-life data suggest that 
normal QALE (Qn) for 33-year-old males is 42.83 years. 
Following Eqs. 4 and 5, the point estimate for PS is 0.71 
(42.83 − 12.25/42.83) and the point estimate for AS is 30.58. 
Following the Dutch guidelines, a cost-effectiveness thresh-
old of €80,000 would apply.
However, estimates of PS and AS are inherently uncer-
tain, since they are calculated using both Qn and Qd , which 
are both uncertain. When a point estimate for PS is used 
to determine the applicable WTP threshold, small differ-
ences can have a sizable impact. In the context of treatment 
T, a PS of 71% (e.g. Qd = 12.25 and Qn = 42.83 ) implies a 
Dutch WTP threshold of €80,000 to be applicable. How-
ever, a value of Qd that is just slightly larger (e.g. Qd = 13, 
PS = 42.83 − 13/42.83 = 0.7, AS = 42.83 − 13 = 29.83) results 
in a WTP threshold of €50,000 in the Netherlands, while the 
two point estimates of Qd in this example may lie well within 
the confidence interval and may even be equally likely. Simi-
larly, the value of Qn is also uncertain, and may impact the 
relevant threshold to be applied and is better represented by 
a distribution than by a point estimate.
To address the uncertainty in Qn , the country-, age- and 
gender-specific mortality rates are combined with utility val-
ues from a random draw of k replications (here 1000) from a 
beta distribution using country-specific published EQ-5D-3L 
standard errors by age and gender [24], resulting in 1000 
estimates of Qn . The uncertainty for Qd is included through 
the probabilistic sensitivity analysis of the health economic 
model or can alternatively be sampled using published mean 
and standard deviation of the undiscounted QALYs in the 
comparator of the model. A simple disease burden calcula-
tion tool (the iMTA Disease Burden Calculator, iDBC) to 
perform these calculations by giving age, gender and the 
number of undiscounted QALYs from the comparator is 
available from the authors.
4  Severity‑Adjusted Probability of Being 
Cost Effective
The severity-adjusted probability of being cost effective 
can be calculated by combining the results of the sampled 
estimates of Qn and Qd with the results of the probabilistic 
sensitivity of a cost-effectiveness model to calculate the net 
monetary benefit at given values for PS and the associated 
threshold using the equations below. That resulting value 
represents the severity-adjusted probability of being cost 
effective (SAPCE).
where
Table 1 illustrates the application of SAPCE using a 
selection of hypothetical outputs of a health economic 
model. In the table, we use the Dutch proposal of PS as an 
indicator of severity, where vs is the PS-based applicable 
threshold for the sampling estimate s , which can take on the 
value €20,000, €50,000 or €80,000 depending on the value 
of PS. Note that the method would also apply to continuous 
differential thresholds, in which case the applicable thresh-
old v in Table 1 would be a unique value for each estimate 
of severity rather than a categorical variable with only three 
possible values. Note also that when the PSA results in a 
skewed distribution, the deterministic estimate of sever-
ity may well be different from the probabilistic estimate of 
severity.
4.1  Example Application
The implications of using (and not using) the SAPCE pro-
cedure in jurisdictions that wish to apply equity weighting 
is demonstrated here. To do so, we introduce a stylized 
example for a hypothetical treatment in, say, oncology in 
the Netherlands and evaluate it using differential thresholds 
based on the current proposed methods in those countries 
and using the new SAPCE to highlight relevant differences 
to the decision-making context.
(7)SAPCEs =
1
n
n∑
s=1
Ys,
Ys =
{
1 if vs × ΔQs − ΔCs ≥ 0
0 if vs × ΔQs − ΔCs < 0
.
2 Note that normative choices regarding the appropriate population to 
calculate severity in as well as the relevant time frame for calculating 
it, remains important. In vaccination, for example, health effects are 
far in the future, uncertain, and affect only a few of the total treated 
population. Hence, calculating severity for preventive treatments 
requires the determination of the appropriate population after which 
the methods presented in this paper can be applied. A discussion that 
recognizes the complexity of the issues relating to these normative 
choices is outside the scope of this paper.
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We use a hypothetical Markov model for an oncological 
treatment at old age (88 years, 50% males) with three health 
states (progression, progression free and dead). The model 
compares current care with a new hypothetical cancer treat-
ment that delays time to progression by about 50%, with 
monthly costs of €110 before progression and €350 after 
progression, and a utility increase of 0.06 in the progression-
free period for the treated group. Probabilistic sensitivity 
analyses are conducted using assumptions on the standard 
errors distributions for the input parameters.
The cost-effectiveness results of the hypothetical oncol-
ogy model with population age of 88 years and 50% males 
are summarized in Table 2.
Estimates of Qn are provided for the Netherlands using 
country-specific mortality rates and quality-of-life estimates 
corrected for age and gender with confidence intervals ana-
lytically derived from the 1000 samplings as described in the 
sections above. At age 88 years, 50% males, Qn is 3.84 [95% 
CI 3.64–4.02]. The estimate of the mean Qd is obtained from 
the probabilistic sensitivity analysis conducted in the hypo-
thetical cost-effectiveness model. Standard of care results 
in a value for Qd of 1.0976 QALYs. From these values, the 
mean AS and PS were calculated including 95% confidence 
intervals, the results of which are provided in Table 3.
According to a deterministic analysis for the Dutch set-
ting, the appropriate WTP threshold for the hypothetical 
new oncology treatment would be €80,000 since PS = 0.71 
(2.74/3.84 = 0.71). However, Table 3 also shows that the 
confidence interval for the point estimate of PS includes 
values < 0.71, which are associated with a €50,000 thresh-
old. Thus, the applicable threshold might also be €50,000 
(the €20,000 threshold was not relevant with a probability of 
zero). In this case, we observed that 340 out of 1000 sampled 
values of PS were 0.4–0.7 and 660 were ≥ 0.71.
Assuming a threshold/WTP of €80,000 per QALY, the 
probability of the new intervention being cost effective is 
about 85%. Assuming a threshold/WTP of €50,000 per 
QALY, the probability is about 3%. The severity-adjusted 
probability of being cost effective is 62.4%. Figure 1 shows 
the standard CEACs for the standard of care (dotted decreas-
ing line) and the intervention (solid increasing line) with the 
two possible thresholds and SAPCE = 0.624 (probability of 
being cost effective given all probable thresholds of 62.4% 
according to the methods described in Table 1). Clearly, the 
use of SAPCE reduces the chance of an incorrect coverage 
decision due to the technology being evaluated against the 
‘wrong’ threshold. Note that the value for SAPCE is placed 
on the Y axis of Fig. 1 to illustrate the difference with the 
probability of being cost-effective with traditional CEACs 
and a deterministic estimation of PS.
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5  Discussion
This paper argues that countries and decision makers that 
wish to apply differential categorical thresholds, based on 
some equity criterion like severity of illness, need to account 
for heterogeneity and uncertainty in the point estimates 
of the appropriate measure, in relation to the appropriate 
threshold. A severity-adjusted probability of being cost 
effective may better reflect the uncertainty and heterogene-
ity regarding the calculations than a point estimate does. 
Reflecting this may lead to better informed decisions that 
take into account both efficiency and equity considerations.
The approach presented here integrates the uncertainty 
in the estimation of appropriately expressed severity of ill-
ness and the uncertainty in the incremental cost-effective-
ness ratio. We presented a standardized approach to address 
uncertainty in two common ways of expressing severity of 
illness—AS and PS. We showed how this uncertainty can be 
integrated with probabilistic sensitivity analyses.
The hypothetical cost-effectiveness model showed the 
relevance of appropriately expressing uncertainty for these 
parameters. In the Dutch situation, a minor change in life 
expectancy with the disease (i.e. 2.70 QALYs lost instead 
of 2.74) slightly lowered the PS estimate (within its con-
fidence interval), causing it to fall into another threshold 
category—thus substantially lowering the applicable cost-
effectiveness threshold. The associated probability of being 
cost effective could range from 85 to 3% for estimates of PS 
that were all within the same confidence interval. We argue 
that neither estimate would be correct and suggest that the 
severity-adjusted probability of being cost effective, which 
was 62.4% in the example, is a better reflection of the prob-
ability of making a correct decision regarding the adoption 
of the technology. Arguably, the use of categorical thresh-
olds rather than continuous ones increases the importance of 
integrating uncertainty since the categorization in a specific 
equity class can have a large impact on the probability of 
being cost effective.
There are several limitations to our study. The first is 
the selection of severity measures used to exemplify the 
procedure. PS is the method of choice in the Dutch guide-
lines as an operationalization of severity in the context 
of reimbursement decisions. Different operationalizations 
have some support in the Netherlands, Norway and the 
UK, and all incorporate both a time and quality com-
ponent [25]. The use of the PS method here follows the 
Dutch guidelines and does not express a preference of this 
method over another by the authors.
The second limitation is difficult to correct, and argu-
ably a small flaw in the calculation of AS and PS as 
described here. Age- and gender-specific QALE for the 
non-ill (Qn) is calculated based on average mortality and 
quality-of-life data that includes the population for which 
severity is being calculated (Qd) . A truly unbiased estimate 
of Qn should be based on mortality and quality-of-life data 
that excludes the population for which Qd is calculated. 
Note that this limitation is not unique to our proposed 
method, but present in any calculation of AS and PS based 
on population norms. Moreover, unless the population 
under evaluation accounts for a notable part of mortality 
and morbidity in the general population, the resulting bias 
is arguably negligible. Should decisions need to be made 
for treatments targeting a highly common condition, such 
Table 2  Hypothetical cost-effectiveness model 0% discounting
ICER incremental cost-effectiveness ratio, QALYs quality-adjusted 
life-years
Incremental costs (€) Incremental QALYs
New treatment 58,432.00 1.8572
Standard of care 10,445.00 1.0976
Incremental 47,987.00 0.7596
ICER €63,176.53
Table 3  Loss in quality-adjusted life at age 88  years with 1.0976 
QALYs remaining
Absolute shortfall [95% CI] Proportional 
shortfall [95% 
CI]
Netherlands 2.74 [2.67–2.82] 0.71 [0.69–0.74]
SAPCE = .624
Fig. 1  Cost-effectiveness acceptability curves at willingness to pay 
(WTP) = 50,000 and 80,000 and severity-adjusted probability of 
being cost effective (SAPCE) of the hypothetical oncology treatment
 M. M. Versteegh et al.
that the estimate of Qn would be noticeably biased, correc-
tions could be made to exclude this bias.
A further limitation is that we used mortality figures 
from 2013; at the time of analysis these were the most 
recent figures that were available for each of the countries 
included in this study in the Human Mortality Database. 
Also, the age- and gender-specific quality-of-life values 
were taken from the EQ-5D-3L, which has since been 
replaced with EQ-5D-5L [26]. Such practical limitations 
can be solved by updating figures as soon as more recent 
or better ones become available.
The incorporation of a severity-based cost-effective-
ness threshold has limitations in and of itself that are not 
addressed by taking uncertainty into account. We have 
worked under the simplifying assumption that we use an 
optimal, flexible budget and social WTP as the appropriate 
threshold. In case of fixed, non-optimal budgets, displace-
ment of existing technologies and their health opportunity 
costs play a role in the decision [27]. In such a context, 
either in a narrow healthcare perspective or a broader soci-
etal perspective, the use of equity weights or differentiated 
valuations of health gains are relevant for both the new 
healthcare intervention as well as the displaced activities. 
More often than not, governments are unable to identify 
the displaced healthcare interventions and, hence, their 
equity weight or social value; this introduces a practical 
issue [28]. As with estimating average opportunity costs 
of marginal spending, the best estimate may be the average 
equity weight of current spending. This is an important 
avenue for future research.
Our study also has some strengths that are worth men-
tioning and overcomes the limitations of a recent publica-
tion regarding the weighting of QALY gains to account for 
distributional concerns [29]. Our study proposed a way to 
address uncertainty and heterogeneity in QALE estimates. 
These methods are robust and do not require strong assump-
tions about Qn . Also, the use of EQ-5D as a source for qual-
ity-of-life values aligns the QALY calculations for severity 
with those of the health economic model. Finally, our study 
keeps the categorical nature of three increasing cost-effec-
tiveness thresholds intact, which facilitates communication 
and avoids linear interpolations between and extrapolations 
beyond threshold values. The methods produced here can, 
however, also be applied to continuous estimates of severity 
rather than categorical ones.
The methods presented here are a quantitative approach 
to the description of severity in the context of reimburse-
ment decisions. In order to enable the quantification, the 
severity criterion has to be well defined and measurable. 
Note that this is true for all quantifications, also when used 
less sophisticatedly.
Our approach can be used in the assessment phase and 
as such does not preclude the use of additional qualitative 
and/or deliberative assessments of severity in an ‘appraisal-
like’ setting. Rather than integrating uncertainty surround-
ing the severity estimate with uncertainty from the health 
economic model, decision makers may prefer to the keep 
these factors separate to facilitate a deliberative ‘weigh-
ing’ of economic and equity considerations. However, also 
in that situation a proper estimate of severity including its 
uncertainty is required. Our approach simply acknowledges 
that when a quantified approach to incorporating severity 
is adopted, it is important to take into account uncertainty 
around the parameters that make up the calculation. The 
severity-adjusted probability of being cost effective as pre-
sented here is suitable for that task.
6  Conclusion
Differential thresholds can represent differential societal 
WTP for QALY gains in those who are more severely ill. 
Estimates of severity, regardless of the underlying sever-
ity principle, are uncertain, and this uncertainty needs 
to be integrated with the uncertainty of the incremental 
cost-effectiveness ratio. Here, we presented a procedure to 
consistently estimate severity across reimbursement dos-
siers, and a procedure to integrate the uncertainty of that 
estimate with the uncertainty in the incremental cost-effec-
tiveness ratio. The resulting severity-adjusted probability 
of being cost effective is better capable of informing deci-
sion makers than one that does not take the uncertainty of 
severity estimates into account.
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